Niraparib - Janssen/Merck/TESARO

Drug Profile

Niraparib - Janssen/Merck/TESARO

Alternative Names: JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Developer Bayer; Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; Janssen; Merck & Co; Myriad Genetics; NeoGenomics; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; TESARO; Thomas Jefferson University; University Health Network; University of Pennsylvania; University of Utah
  • Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer
  • Phase II Endometrial cancer; Non-small cell lung cancer; Prostate cancer
  • Phase I/II Pancreatic cancer
  • Phase I Ewing's sarcoma; Solid tumours
  • No development reported Haematological malignancies

Most Recent Events

  • 11 Apr 2018 Niraparib market licensed to MediSon Pharma in Israel (except for Prostate cancer)
  • 05 Apr 2018 Takeda Pharmaceutical plans a phase I trial for Solid tumours in Japan , (JapicCTI-183911)
  • 26 Mar 2018 Adverse events and efficacy data from a retrospective analysis of the phase III ENGOT-OV16/NOVA trial in Ovarian cancer released by TESARO
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top